HCG Stock Overview
Provides medical and healthcare services focusing on cancer and fertility in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
HealthCare Global Enterprises Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹467.60 |
| 52 Week High | ₹519.50 |
| 52 Week Low | ₹314.00 |
| Beta | 0.29 |
| 11 Month Change | 5.97% |
| 3 Month Change | 29.08% |
| 1 Year Change | 24.31% |
| 33 Year Change | 80.72% |
| 5 Year Change | 313.44% |
| Change since IPO | 173.45% |
Recent News & Updates
Recent updates
We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned
Sep 19
HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next
Feb 11We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation
Sep 14A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)
Sep 05HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price
May 17Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?
Jun 24Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings
Jun 03Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?
Dec 08What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?
Jun 25Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares
Mar 14The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On
Mar 03Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt
Jan 27How Many HealthCare Global Enterprises Limited (NSE:HCG) Shares Did Insiders Buy, In The Last Year?
Dec 23
Shareholder Returns
| HCG | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 3.9% | 2.6% | 0.8% |
| 1Y | 24.3% | 48.1% | 36.2% |
Return vs Industry: HCG underperformed the Indian Healthcare industry which returned 48.1% over the past year.
Return vs Market: HCG underperformed the Indian Market which returned 36.2% over the past year.
Price Volatility
| HCG volatility | |
|---|---|
| HCG Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: HCG has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HCG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 6,150 | Raj Gore | www.hcgoncology.com |
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand that provides inpatient and outpatients treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care.
HealthCare Global Enterprises Limited Fundamentals Summary
| HCG fundamental statistics | |
|---|---|
| Market cap | ₹65.60b |
| Earnings (TTM) | ₹526.10m |
| Revenue (TTM) | ₹19.77b |
123.9x
P/E Ratio3.3x
P/S RatioIs HCG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCG income statement (TTM) | |
|---|---|
| Revenue | ₹19.77b |
| Cost of Revenue | ₹12.35b |
| Gross Profit | ₹7.42b |
| Other Expenses | ₹6.89b |
| Earnings | ₹526.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 09, 2024
| Earnings per share (EPS) | 3.78 |
| Gross Margin | 37.51% |
| Net Profit Margin | 2.66% |
| Debt/Equity Ratio | 147.3% |
How did HCG perform over the long term?
See historical performance and comparison